Insider Selling: Xencor, Inc. (NASDAQ:XNCR) Director Sells 2,993 Shares of Stock

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) Director Richard J. Ranieri sold 2,993 shares of the company's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $9.22, for a total value of $27,595.46. Following the completion of the transaction, the director now directly owns 19,183 shares of the company's stock, valued at approximately $176,867.26. This trade represents a 13.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Xencor Price Performance

Shares of XNCR stock traded up $0.05 on Thursday, reaching $8.36. The company's stock had a trading volume of 835,269 shares, compared to its average volume of 667,672. The stock's fifty day simple moving average is $9.07 and its 200-day simple moving average is $14.70. Xencor, Inc. has a 1 year low of $7.16 and a 1 year high of $27.24. The company has a market capitalization of $594.98 million, a price-to-earnings ratio of -2.73 and a beta of 0.87. The company has a current ratio of 5.89, a quick ratio of 5.89 and a debt-to-equity ratio of 0.16.

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.06). Xencor had a negative net margin of 181.17% and a negative return on equity of 31.94%. The business had revenue of $32.73 million for the quarter, compared to the consensus estimate of $23.44 million. During the same quarter last year, the business earned ($1.11) EPS. Xencor's revenue for the quarter was up 104.6% compared to the same quarter last year. Analysts forecast that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Sterling Capital Management LLC increased its stake in Xencor by 732.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 1,040 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Xencor in the 4th quarter valued at approximately $34,000. State of Wyoming purchased a new position in shares of Xencor in the 1st quarter worth approximately $34,000. CWM LLC boosted its holdings in shares of Xencor by 195.5% in the 1st quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company's stock worth $36,000 after purchasing an additional 2,231 shares during the period. Finally, AlphaQuest LLC bought a new position in shares of Xencor during the 1st quarter valued at approximately $56,000.

Analyst Ratings Changes

A number of research analysts recently commented on XNCR shares. William Blair started coverage on Xencor in a report on Monday, April 21st. They issued an "outperform" rating on the stock. Wedbush reiterated an "outperform" rating and set a $31.00 price objective on shares of Xencor in a research report on Wednesday, April 30th. Wall Street Zen downgraded shares of Xencor from a "hold" rating to a "sell" rating in a report on Friday, March 14th. Barclays dropped their target price on shares of Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a research report on Thursday, May 8th. Finally, Wells Fargo & Company reduced their price target on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Two research analysts have rated the stock with a sell rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $28.00.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.